💊Fujitsu Develops Molecular Simulation Technology to Effectively Create New Drug Candidates

By Drugs, Pharmaceutical

💊Fujitsu Develops Molecular Simulation Technology to Effectively Create New Drug Candidates

Fujitsu Laboratories Ltd. and Fujitsu Limited today announced the development of molecular simulation technology for drug discovery that can accurately estimate binding affinity, which represents the degree to which proteins that can cause diseases (target proteins) bind to chemical substances that could become candidate drugs.

Fujitsu Global

http://www.fujitsu.com/global/about/resources/news/press-releases/2018/0507-02.html

More from tokioX :

  1. Takeda receives clearance from the State Administration for Market Regulation in China for the proposed acquisition of Shire plc
  2. FDA: Eisai ‘s “Rembima” approved as a hepatocellular cancer drug
  3. EISAI AND BIOGEN ANNOUNCE POSITIVE TOPLINE RESULTS OF THE FINAL ANALYSIS FOR BAN2401 AT 18 MONTHS
  4. 💊Takeda Statement Regarding Improved Proposal for Shire plc
  5. 🔬Nikon | News | Nikon Corporation and Yumanity Therapeutics Enter Contract for the Commission Development of Drug Discovery Assay System in Neurodegenerative Diseases
  6. 💊FDA & PHARMA TODAY
  7. 💊FDA PHARMA TODAY